Search Results - "Huang, XianGao"

Refine Results
  1. 1

    A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma by Martin, Peter, Bartlett, Nancy L., Blum, Kristie A., Park, Steven, Maddocks, Kami, Ruan, Jia, Ridling, LeAnn, Dittus, Christopher, Chen, Zhengming, Huang, Xiangao, Inghirami, Giorgio, DiLiberto, Maurizio, Chen-Kiang, Selina, Leonard, John P.

    Published in Blood (14-03-2019)
    “…Single-agent ibrutinib is active in patients with previously treated mantle cell lymphoma (MCL); however, nearly half of all patients experience treatment…”
    Get full text
    Journal Article
  2. 2

    Histone demethylase KDM2A is a selective vulnerability of cancers relying on alternative telomere maintenance by Li, Fei, Wang, Yizhe, Hwang, Inah, Jang, Ja-Young, Xu, Libo, Deng, Zhong, Yu, Eun Young, Cai, Yiming, Wu, Caizhi, Han, Zhenbo, Huang, Yu-Han, Huang, Xiangao, Zhang, Ling, Yao, Jun, Lue, Neal F., Lieberman, Paul M., Ying, Haoqiang, Paik, Jihye, Zheng, Hongwu

    Published in Nature communications (29-03-2023)
    “…Telomere length maintenance is essential for cellular immortalization and tumorigenesis. 5% − 10% of human cancers rely on a recombination-based mechanism…”
    Get full text
    Journal Article
  3. 3

    A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function by Liu, Yaobin, Huang, Xiangao, He, Xian, Zhou, Yanqing, Jiang, Xiaogang, Chen‐Kiang, Selina, Jaffrey, Samie R., Xu, Guoqiang

    Published in The FASEB journal (01-12-2015)
    “…ABSTRACT The immunomodulatory drug (IMiD) thalidomide and its structural analogs lenalidomide and pomalidomide are highly effective in treating clinical…”
    Get full text
    Journal Article
  4. 4
  5. 5

    A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma by Martin, Peter, Ruan, Jia, Furman, Richard, Rutherford, Sarah, Allan, John, Chen, Zhengming, Huang, Xiangao, DiLiberto, Maurizio, Chen-Kiang, Selina, Leonard, John P.

    Published in Leukemia & lymphoma (15-10-2019)
    “…In mantle cell lymphoma (MCL), cyclin D1 combines with CDK4/6 to phosphorylate Rb, releasing a break on the G1 to S phase cell cycle. Palbociclib is a…”
    Get full text
    Journal Article
  6. 6
  7. 7

    A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model by Menu, Eline, Garcia, Josefina, Huang, Xiangao, Di Liberto, Maurizio, Toogood, Peter L, Chen, Isan, Vanderkerken, Karin, Chen-Kiang, Selina

    Published in Cancer research (Chicago, Ill.) (15-07-2008)
    “…Multiple myeloma (MM) remains incurable partly because no effective cell cycle-based therapy has been available to both control tumor cell proliferation and…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Caspase-8 Inhibition Prevents the Cleavage and Degradation of E3 Ligase Substrate Receptor Cereblon and Potentiates Its Biological Function by Zhou, Liang, Yu, Wenjun, Jayabalan, David S, Niesvizky, Ruben, Jaffrey, Samie R, Huang, Xiangao, Xu, Guoqiang

    “…Cereblon (CRBN), a substrate receptor of cullin 4-RING E3 ligase (CRL4), mediates the ubiquitination and degradation of constitutive substrates and…”
    Get full text
    Journal Article
  10. 10

    Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors by Bretz, Jamieson, Garcia, Josefina, Huang, Xiangao, Kang, Lin, Zhang, Yang, Toellner, Kai-Michael, Chen-Kiang, Selina

    Published in Blood (17-02-2011)
    “…Inhibition of Cdk4/Cdk6 by p18INK4c (p18) is pivotal for generation of noncycling immunoglobulin (Ig)-secreting plasma cells (PCs). In the absence of p18,…”
    Get full text
    Journal Article
  11. 11

    Caspase-8 Regulates the Antimyeloma Activity of Bortezomib and Lenalidomide by Zhou, Liang, Huang, Xiangao, Niesvizky, Ruben, Pu, Zhongjian, Xu, Guoqiang

    “…Proteasome inhibitors and immunomodulatory drugs (IMiDs) are two major types of drugs for the treatment of multiple myeloma. Although different combination…”
    Get full text
    Journal Article
  12. 12

    Blind reconnaissance of the pseudo-random sequence in DS/SS signal with negative SNR by Huang, XianGao, Huang, Wei, Wang, Chao, Lü, ZeJun, Hu, YanHua

    Published in Science China. Information sciences (01-06-2007)
    “…This paper introduces a new theory and algorithm that can be used in blind detection of the carrier wave signal and the pseudo-random sequence of the direct…”
    Get full text
    Journal Article
  13. 13

    Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy by Wang, Kevin, Huang, Xiangao, Di Liberto, Maurizio, Chen-Kiang, Selina

    “…Cell cycle dysregulation caused by aberrant cyclin D1 and CDK4 expression is a major determinant for proliferation of cancer cells in mantle cell lymphoma…”
    Get full text
    Journal Article
  14. 14

    Cell Cycle Dysregulation in Mantle Cell Lymphoma by Wang, Kevin, Huang, Xiangao, Di Liberto, Maurizio, Chen-Kiang, Selina

    “…Cell cycle dysregulation caused by aberrant cyclin D1 and CDK4 expression is a major determinant for proliferation of cancer cells in mantle cell lymphoma…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17

    Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1 by Huang, Xiangao, Di Liberto, Maurizio, Cunningham, Adam F, Kang, Lin, Cheng, Shuhua, Ely, Scott, Liou, Hsiou-chi, Maclennan, Ian C M, Chen-Kiang, Selina

    “…Cell-cycle entry is critical for homeostatic control in physiologic response of higher organisms but is not well understood. The antibody response begins with…”
    Get full text
    Journal Article
  18. 18

    Disrupting GRINL1A Association with Cereblon Accelerates IKZF1/3 Degradation and IMiD Killing of Mantle Cell Lymphoma Cells By CDK4/6 Inhibition by Zhao, Nicole, Di Liberto, Maurizio, Elemento, Olivier, Chen-Kiang, Selina, Huang, Xiangao

    Published in Blood (13-11-2019)
    “…Lenalidomide (Len) and Pomalidomide (Pom) are immunomodulatory drugs (IMiDs) used for the treatment of multiple myeloma (MM) and have efficacy in other…”
    Get full text
    Journal Article
  19. 19

    Harnessing Btki Therapy By CDK4/6i Control of T Effector Memory Cells and T Cell Surveillance in Mantle Cell Lymphoma by Di Liberto, Maurizio, Hu, Yang, Huang, Xiangao, Inghirami, Giorgio, Wang, Kevin, Lee, Christina, Maddocks, Kami J., Blum, Kristie A., Ruan, Jia, Leonard, John P., Bartlett, Nancy L., Martin, Peter, Elemento, Olivier, Chen-Kiang, Selina

    Published in Blood (02-11-2023)
    “…Drug resistance remains a formidable challenge in mantle cell lymphoma (MCL). Cell cycle dysregulation driven by aberrant Cyclin D1 and CDK4 expression is a…”
    Get full text
    Journal Article
  20. 20

    Dynamic Immune Surveillance in Durable Clinical Response to Combined BTK and BCL2 Inhibition in MCL at Longitudinal Single-Cell Resolution by Wang, Kevin, Di Liberto, Maurizio, Hu, Yang, Huang, Xiangao, Koldej, Rachel M, Ritchie, David, Martin, Peter, Inghirami, Giorgio, Elemento, Olivier, Tam, Constantine S., Chen-Kiang, Selina

    Published in Blood (23-11-2021)
    “…Combined inhibition of BTK with ibrutinib and BCL2 with venetoclax is one of the most promising therapies for B cell malignancies, especially mantle cell…”
    Get full text
    Journal Article